Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.67 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.66 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.66 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.53 |
| ▸ | ITGAV | P06756 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5323583 | 1.00 | FOLH1 (0.67) | FOLH1SIRT2SIRT1SIRT5HTT | |
| SCHEMBL9828826 | 0.99 | FOLH1 (0.69) | FOLH1SIRT2SIRT1SIRT5HTT | |
| SCHEMBL5711292 | 0.99 | FOLH1 (0.69) | FOLH1SIRT2SIRT1SIRT5HTT | |
| SCHEMBL5711173 | 0.95 | FOLH1 (0.67) | FOLH1SIRT2SIRT1SIRT5HTT | |
| SCHEMBL5711264 | 0.95 | FOLH1 (0.67) | FOLH1SIRT2SIRT1SIRT5HTT | |
| SCHEMBL6278137 | 0.95 | FOLH1 (0.67) | FOLH1SIRT2SIRT1SIRT5HTT | |
| SCHEMBL8387978 | 0.92 | FOLH1 (0.65) | FOLH1SIRT2SIRT1SIRT5ECE1 | |
| SCHEMBL910423 | 0.89 | FOLH1 (0.70) | FOLH1SIRT2SIRT1MMEECE1 | |
| SCHEMBL910232 | 0.89 | FOLH1 (0.70) | FOLH1SIRT2SIRT1MMEECE1 | |
| SCHEMBL910233 | 0.89 | FOLH1 (0.70) | FOLH1SIRT2SIRT1MMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4086272-A1 | METHODS FOR PRODUCING CYCLIC COMPOUNDS COMPRISING N-SUBSTITUTED AMINO ACID RESIDUES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-11-09 | — | — | EP | disclosed |
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
| WO-2007143822-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-21 | — | — | WO | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | HDAC1, HDAC5, HDAC11 | FOLH1 2876/4885SIRT2 44/4885SIRT1 21/4885 |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | FOLH1 2522/4885SIRT2 52/4885SIRT1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.